Who
Irina Antonijevic
Director
Company insider
Files Form 4 as: Director, Biohaven; Director, Biohaven Pharmaceutical Holding Co.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $460K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 11 May 2022
- Last trade
- 28 Apr 2026
- Last filed
- 30 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 28 Apr 2026filed 30 Apr 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,693 at $0.00 | filing |
| 5 May 2025filed 7 May 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,716 at $0.00 | filing |
| 30 Apr 2024filed 2 May 2024 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,592 at $0.00 | filing |
| 29 Dec 2023filed 29 Dec 2023 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 29 Dec 2023filed 29 Dec 2023 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 29 Dec 2023filed 29 Dec 2023 | BHVN BiohavenBiotechnology | SEC FORM 4 Sold | $460K11,000 at $41.79 | filing |
| 2 May 2023filed 4 May 2023 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,906 at $0.00 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN BiohavenBiotechnology | SEC FORM 4 Code J | —2,535 at $0.00 | filing |
| 3 Oct 2022filed 3 Oct 2022 | Biohaven Pharmaceutical Holding Cooption or derivative | SEC FORM 4 Code D | —5,070 | filing |
| 11 May 2022filed 12 May 2022 | Biohaven Pharmaceutical Holding Cooption or derivative | SEC FORM 4 Code A | —5,070 at $0.00 | filing |
News
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target UpgradeBHVN · insidermonkey.com · 23 Oct 2026Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock UpBHVN · rttnews.com · 22 Oct 2026Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug VyglxiaBHVN · ibtimes.com.au · 22 Oct 2026
0 headlines in the last 90 days name Irina Antonijevic; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.